The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
 
Susana N. Banerjee
Stock and Other Ownership Interests - Perci Health
Honoraria - Amgen; AstraZeneca; Clovis Oncology; GlaxoSmithKline; Immunogen; Mersana; MSD Oncology; Novocure; Pfizer; Roche; Takeda
Consulting or Advisory Role - Astrazeneca; Epsilogen; GlaxoSmithKline; Immunogen; Mersana; MSD Oncology; Novartis; OncXerna Therapeutics; Regeneron; Seagen; Shattuck Labs
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline
 
Kari Lassen Ring
No Relationships to Disclose
 
Els Van Nieuwenhuysen
Consulting or Advisory Role - Regeneron (Inst)
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst)
 
Michel Fabbro
Honoraria - AstraZeneca
Consulting or Advisory Role - Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - Roche
 
Carol Aghajanian
Consulting or Advisory Role - AstraZeneca/Merck; Eisai; Repare Therapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst)
 
Ana Oaknin
Consulting or Advisory Role - AGENUS; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera; Eisai; EMD Serono; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Merck Sharp & Dohme; Mersana; Novocure; PharmaMar; prIME Oncology; Roche; Roche; Seagen; Shattuck Labs; Sutro Biopharma; Tesaro
Research Funding - Abbvie (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); PharmaMar (Inst); Regeneron (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche
 
Nicoletta Colombo
Employment - Sarepta Therapeutics (I)
Honoraria - Advaxis; Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novartis; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech
Consulting or Advisory Role - Advaxis; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech
 
Alessandro Santin
Consulting or Advisory Role - Merck; R-Pharm; Tesaro
Research Funding - Boehringer Ingelheim (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Merck (Inst); Puma Biotechnology (Inst); R-Pharm (Inst); Tesaro (Inst); Verastem (Inst)
 
Andrew R. Clamp
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Immunogen
Speakers' Bureau - Clovis Oncology; GlaxoSmithKline; MSD/AstraZeneca
Research Funding - Advenchen Laboratories (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Merck (Inst); Pfizer (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Tesaro
 
Kathleen N. Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Great Debates and Updates; Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - AADi; Alkermes (Inst); AstraZeneca; Blueprint Medicines (Inst); Caris Life Sciences; Clovis Oncology; Eisai; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); Hengrui Pharmaceutical; I-Mab (Inst); Immunogen; InxMed (Inst); Iovance Biotherapeutics; Merck; Mereo BioPharma; Mersana (Inst); Myriad Genetics; Novartis; Novartis/Pfizer; Onconova Therapeutics; OncXerna Therapeutics; VBL Therapeutics; Verastem/Pharmacyclics
Research Funding - Agenus (Inst); Amgen (Inst); artios (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo/Lilly (Inst); Genentech (Inst); Immunocore (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline
Other Relationship - GOG Partners (Inst)
 
Peter Graham Rose
No Relationships to Disclose
 
David M. O'Malley
Consulting or Advisory Role - Adaptimmune; Agenus; Arcus Biosciences; AstraZeneca; Atossa Therapeutics; BBI Healthcare; Celsion; Clovis Oncology; Corcept Therapeutics; DualityBio; Eisai; Elevar Therapeutics; Genelux; Genentech/Roche; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; InxMed; Jazz Pharmaceuticals; Laekna Therapeutics; Merck; Mersana; Novartis; Novocure; Novocure; OncoC4; Onconova Therapeutics; Regeneron; Roche; Seagen; Sutro Biopharma; Takeda; Toray Industries; Umoja Biopharma; VBL Therapeutics; Verastem; Vincerx Pharma
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); SeaGen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)
 
Hye Sook Chon
Honoraria - Curio Science; Envision Communications; Guidepoint Global; MJH Healthcare Holdings, LLC
Consulting or Advisory Role - Envision Communications
Travel, Accommodations, Expenses - Agenus
 
Erin A Salinas
No Relationships to Disclose
 
Emily N Prendergast
Consulting or Advisory Role - GOG Foundation; HERON
 
Stephanie Lustgarten
Employment - Verastem
Stock and Other Ownership Interests - Verastem
 
Manuel Rodrigues
Honoraria - Immunocore
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
Research Funding - Daiichi Sankyo/Astra Zeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Christine Gennigens
Honoraria - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Ipsen; MSD; Pfizer; PharmaMar
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Ipsen; MSD
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Ipsen; MSD; Pfizer; PharmaMar
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Macrogenics; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Consulting or Advisory Role - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Rachel N. Grisham
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Corcept Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Intellisphere; Myriad Genetics; Signatera; SpringWorks Therapeutics; Verastem
Research Funding - Bayer (Inst); Context Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); SpringWorks Therapeutics (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - EMD Serono
Other Relationship - Aptitude Health; Cardinal Health; MCM Education; OncLive; Prime Oncology
(OPTIONAL) Uncompensated Relationships - Verastem